Cell Therapy As Target Therapy Against Colon Cancer Stem Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 May 13

PMID 37175871

Authors

Elsa N Garza Trevino

Adriana G Quiroz Reyes

Juan Antonio Rojas Murillo

David A de la Garza Kalife

Paulina Delgado Gonzalez

Jose F Islas

Ana Esther Estrada Rodriguez

Carlos A Gonzalez Villarreal

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with properties, such as self-renewal, differentiation, and tumorigenicity. CSCs have been proposed as a plausible therapeutic target as they are responsible for tumor recurrence, metastasis, and conventional therapy resistance. Selectively targeting CSCs is a promising strategy to eliminate the propagation of tumor cells and impair overall tumor development. Recent research shows that several immune cells play a crucial role in regulating tumor cell proliferation by regulating different CSC maintenance or proliferation pathways. There have been great advances in cellular immunotherapy using T cells, natural killer (NK) cells, macrophages, or stem cells for the selective targeting of tumor cells or CSCs in colorectal cancer (CRC). This review summarizes the CRC molecular profiles that may benefit from said therapy and the main vehicles used in cell therapy against CSCs. We also discuss the challenges, limitations, and advantages of combining conventional and/or current targeted treatments in the late stages of CRC.

Citing Articles

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.

Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).

PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V Cells. 2025; 14(3).

PMID: 39936958 PMC: 11817869. DOI: 10.3390/cells14030166.

Exploring the role of Fusobacterium nucleatum in colorectal cancer: implications for tumor proliferation and chemoresistance.

Dadgar-Zankbar L, Elahi Z, Shariati A, Khaledi A, Razavi S, Khoshbayan A Cell Commun Signal. 2024; 22(1):547.

PMID: 39548531 PMC: 11566256. DOI: 10.1186/s12964-024-01909-y.

A Two-Stage Transferred Cold Atmospheric Plasma as a Unique Therapeutic Strategy for Targeting Colon Cancer Stem Cells.

Soulat A, Mohsenpour T, Roshangar L, Naghshara H Adv Pharm Bull. 2024; 14(2):400-411.

PMID: 39206394 PMC: 11347729. DOI: 10.34172/apb.2024.041.

Tumor cell stemness in gastrointestinal cancer: regulation and targeted therapy.

Yang K, Yi T Front Mol Biosci. 2024; 10:1297611.

PMID: 38455361 PMC: 10918437. DOI: 10.3389/fmolb.2023.1297611.

References

Li W, Zhang N, Jin C, Long M, Rajabi H, Yasumizu Y . MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI Insight. 2020; 5(12). PMC: 7406273. DOI: 10.1172/jci.insight.137112. View

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

Veselov V, Nosyrev A, Jicsinszky L, Alyautdin R, Cravotto G . Targeted Delivery Methods for Anticancer Drugs. Cancers (Basel). 2022; 14(3). PMC: 8833699. DOI: 10.3390/cancers14030622. View

Aparicio C, Belver M, Enriquez L, Espeso F, Nunez L, Sanchez A . Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. Int J Mol Sci. 2021; 22(21). PMC: 8583883. DOI: 10.3390/ijms222111781. View

Feng Y, Dai X, Li X, Wang H, Liu J, Zhang J . EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. Cell Prolif. 2012; 45(5):413-9. PMC: 6495284. DOI: 10.1111/j.1365-2184.2012.00837.x. View

von Locquenghien M, Rozalen C, Celia-Terrassa T . Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest. 2021; 131(1). PMC: 7773346. DOI: 10.1172/JCI143296. View

Ho C, Wu M, Chen M, Lin S, Yen Y, Hung S . Combination of Mesenchymal Stem Cell-Delivered Oncolytic Virus with Prodrug Activation Increases Efficacy and Safety of Colorectal Cancer Therapy. Biomedicines. 2021; 9(5). PMC: 8153168. DOI: 10.3390/biomedicines9050548. View

Rossignoli F, Spano C, Grisendi G, Foppiani E, Golinelli G, Mastrolia I . MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Theranostics. 2019; 9(2):436-448. PMC: 6376176. DOI: 10.7150/thno.27576. View

Shokouhifar A, Firouzi J, Nouri M, Sarab G, Ebrahimi M . NK cell upraise in the dark world of cancer stem cells. Cancer Cell Int. 2021; 21(1):682. PMC: 8684645. DOI: 10.1186/s12935-021-02400-1. View

10.

Wang H, Tian T, Zhang J . Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis. Int J Mol Sci. 2021; 22(16). PMC: 8395168. DOI: 10.3390/ijms22168470. View

11.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

12.

Zhu Y, Cheng M, Yang Z, Zeng C, Chen J, Xie Y . Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts. Drug Des Devel Ther. 2014; 8:2449-62. PMC: 4267519. DOI: 10.2147/DDDT.S71466. View

13.

Abbasian M, Mousavi E, Arab-Bafrani Z, Sahebkar A . The most reliable surface marker for the identification of colorectal cancer stem-like cells: A systematic review and meta-analysis. J Cell Physiol. 2018; 234(6):8192-8202. DOI: 10.1002/jcp.27619. View

14.

DAloia M, Zizzari I, Sacchetti B, Pierelli L, Alimandi M . CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018; 9(3):282. PMC: 5833816. DOI: 10.1038/s41419-018-0278-6. View

15.

Portillo A, Hogg R, Poznanski S, Rojas E, Cashell N, Hammill J . Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. iScience. 2021; 24(6):102619. PMC: 8193615. DOI: 10.1016/j.isci.2021.102619. View

16.

Chan L, Dass S, Tye G, Imran S, Wan Kamarul Zaman W, Nordin F . CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review. Biomedicines. 2022; 10(4). PMC: 9024487. DOI: 10.3390/biomedicines10040804. View

17.

Xu J, Meng Q, Sun H, Zhang X, Yun J, Li B . HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. Cell Death Dis. 2021; 12(12):1109. PMC: 8627513. DOI: 10.1038/s41419-021-04100-0. View

18.

Snajdauf M, Havlova K, Vachtenheim Jr J, Ozaniak A, Lischke R, Bartunkova J . The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Front Mol Biosci. 2021; 8:628332. PMC: 8006409. DOI: 10.3389/fmolb.2021.628332. View

19.

Guo M, Luo B, Pan M, Li M, Xu H, Zhao F . Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer. Int Immunopharmacol. 2020; 88:106850. DOI: 10.1016/j.intimp.2020.106850. View

20.

Chanmee T, Ontong P, Konno K, Itano N . Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014; 6(3):1670-90. PMC: 4190561. DOI: 10.3390/cancers6031670. View